TAG:
aco
Intermountain Seeks Shared Accountability
By Joseph Burns | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Intermountain Healthcare is one of the nation’s largest and most respected institutions. Its quality improvement efforts are well documented. Intermountain is pursuing an ambitious goal to limit cost increases to the rate of inflation. To reach this goal, every clinical dep…
Boosting the Lab’s Role in Collaborative Care
By Joseph Burns | From the Volume XX No. 1 – January 22, 2013 Issue
CEO SUMMARY: Collaborative care is an essential element of accountable care organizations (ACO) and other emerging models of integrated clinical care. At MedCentral Health System, one clinical chemist has held a key place on the physician team that develops order sets and clinical alerts….
Anticipating 2013 Trends in Clinical Lab and Pathology
By Robert Michel | From the Volume XX No. 1 – January 22, 2013 Issue
CEO SUMMARY: Biggest news for 2013 will the impact of significant price cuts for both clinical lab and anatomic pathology testing services. But the bad news doesn’t stop there. Employers and private payers will be more aggressive in taking steps to reduce what they spend on lab testing….
December 31, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. 18 – December 31, 2012 Issue
It is likely that the latest lab acquisition by Bio-Reference Laboratories, Inc. (BRLI) is for the purpos…
PAML, Pathology and New Opportunities
By R. Lewis Dark | From the Volume XIX No. 17 – December 10, 2012 Issue
BY ANY MEASURE, MAJOR CHANGES ARE COMING to the profession of laboratory medicine. I assume that you are familiar with most of the trends, healthcare reforms, and significant reductions in lab test reimbursement that appear regularly in the headlines. Many of these developments are unfavorable to th…
RDX Alters Business Plan Due to Lab Market Changes
By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue
CEO SUMMARY: Executives at Regional Diagnostic Laboratories (RDX) made a splash last May when they announced the new company’s plans to acquire hospital laboratory outreach programs, backed by a capital commitment of $250 million. Now, in recognition of swift changes in the lab test mar…
Of 88305-TC and Other Bad News for Pathology Labs
By R. Lewis Dark | From the Volume XIX No. 16 – November 19, 2012 Issue
BY NOW, VIRTUALLY ALL PATHOLOGISTS ARE AWARE of the announced cut in Medicare reimbursement for the technical component (TC) of CPT 88305. Effective on January 1, 2012, Medicare will pay 52% less for this CPT code. From the prior level of $69.78, the new reimbursement will be $33.70. As news of this…
Memorial Hermann’s Health Info Exchange Helps Lab Outreach
By Joseph Burns | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: In Houston, Memorial Hermann Healthcare System has put together a health information exchange (HIE) to serve the Houston market. By design, this HIE not only gives physicians immediate access to a wide variety of patient data, but also supports the type of workflow required f…
Ampersand Buys Calloway Labs, Enters Pain Management Market
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
URINE DRUG TESTING for pain management may be a challenging business for clinical labs given that compliance officers in the states and in the federal government have successfully pursued lab compliance abuses in this line of business in recent years. Now comes news that private equity firm …
Narrower Provider Networks Topic during Quest Conference Call
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
SINCE MAY 1, 2012, the nation’s largest clinical laboratory company has had a new CEO, who is Stephen H. Rusckowski. The company’s second quarter conference call provided an opportunity to learn more about how he views Quest Diagnostics Incorporated. Conducted on July 19, the fi…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized